Key takeaway: The earnings conference call for NATCO Pharma Limited, held on August 14, 2026, discussed the company's financial performance for Q1 FY27. Management reported consolidated total revenues of INR794.4 crores, a decline from INR1,390.6 crores in the same quarter last year, primarily due to lower Lenalidomide revenue. However, there was double-digit growth in the base business. EBITDA for the quarter was INR245.7 crores, with an EBITDA margin of 30.9%. Profit after tax was INR206.5 crores, down from INR269 crores in the previous quarter, which had included a one-time tax benefit. The company highlighted strong growth in its Brazil business, with revenues increasing by 180%. Management also discussed the acquisition of an additional stake in Adcock Ingram, aiming to strengthen its position in the South African market. The call concluded with a Q&A session addressing various operational aspects and future plans.

Key takeaway: During the earnings conference call held on May 29, 2026, management reported that Natco Pharma Limited recorded consolidated total revenue of INR4,375.9 crores for the fiscal year ending March 31, 2026, a decrease from INR4,784 crores the previous year. The net profit for the year was INR1,418.5 crores, down from INR1,883.4 crores. For Q4 FY '26, the company reported net revenue of INR816.9 crores and a profit of INR269 crores, both lower than the same period last year. Management noted a one-time benefit of INR115 crores due to a shift to a new tax regime. They discussed challenges related to the competitive landscape, particularly with the launch of pomalidomide and the impact of increased freight costs due to geopolitical issues. Management also highlighted ongoing investments in R&D and potential future growth from new product launches, particularly in Brazil and South Africa.

Key takeaway: During the earnings conference call held on February 12, 2026, management reported that NATCO Pharma Limited achieved consolidated total revenue of INR 705.4 crores for Q3 FY25-26, an increase from INR 651.1 crores in the same quarter of the previous year. EBITDA was reported at INR 216.8 crores, with a margin of 30.7%, and net profit was INR 151.3 crores. Management discussed the ongoing approval process for GLP-1 products and indicated that they are currently outsourcing fill and finish capacity. They also mentioned plans for further acquisitions, emphasizing the importance of maintaining cash reserves for potential large transactions. The company declared an interim dividend of INR 1.5 per equity share. Management highlighted the strong performance in emerging markets and the anticipated benefits from the Adcock Ingram acquisition, while also addressing ongoing litigation and product approvals.

Key takeaway: The investor presentation for NATCO Pharma Limited's Q3 FY26 reported key financial highlights, including an EBITDA of INR 2,168 million and an EBITDA margin of 30.7%. The profit after tax for Q3 FY26 was INR 1,513 million, with earnings per share at INR 8.46. Total revenue for the quarter was INR 7,054 million, with significant contributions from pharma export formulations and domestic pharma formulations. The presentation noted the strategic acquisition of a 35.75% stake in Adcock Ingram Holdings Limited, which contributed to NATCO's financials. Additionally, the company launched Risdiplam for treating Spinal Muscular Atrophy and outlined its product pipeline, including several Para IV products. The document emphasized ongoing investments in cell and gene therapy, highlighting various partnerships and clinical trials in progress.